FY2027 EPS Estimates for Novartis Lowered by Zacks Research

Novartis AG (NYSE:NVS) – Research analysts at Zacks Research lowered their FY2027 earnings per share estimates for shares of Novartis in a research note issued to investors on Friday, May 8th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $9.73 for the year, down from their previous estimate of $9.79. The consensus estimate for Novartis’ current full-year earnings is $8.85 per share.

Other equities analysts have also issued reports about the stock. Argus raised shares of Novartis from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a research report on Wednesday, March 11th. Wall Street Zen lowered shares of Novartis from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Sanford C. Bernstein raised shares of Novartis to a “hold” rating in a report on Thursday, March 19th. Weiss Ratings downgraded shares of Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research report on Wednesday, April 29th. Finally, TD Cowen reissued a “hold” rating on shares of Novartis in a research report on Tuesday, February 17th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $141.20.

Novartis Trading Down 0.6%

Shares of Novartis stock opened at $145.11 on Tuesday. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.65 and a current ratio of 0.85. The firm has a 50-day moving average of $152.36 and a 200-day moving average of $144.51. Novartis has a 52-week low of $104.93 and a 52-week high of $170.46. The stock has a market cap of $276.89 billion, a PE ratio of 20.79, a PEG ratio of 2.56 and a beta of 0.46.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Monday, April 27th. The company reported $1.99 EPS for the quarter, missing analysts’ consensus estimates of $2.11 by ($0.12). Novartis had a net margin of 24.87% and a return on equity of 38.82%. The firm had revenue of $13.52 billion during the quarter, compared to analyst estimates of $13.44 billion. During the same period in the prior year, the company earned $2.28 earnings per share. The business’s quarterly revenue was down .9% compared to the same quarter last year.

Hedge Funds Weigh In On Novartis

Several hedge funds have recently bought and sold shares of NVS. Archer Investment Corp boosted its position in shares of Novartis by 93.0% during the 1st quarter. Archer Investment Corp now owns 166 shares of the company’s stock worth $25,000 after acquiring an additional 80 shares in the last quarter. Arlington Trust Co LLC acquired a new position in Novartis during the fourth quarter valued at approximately $25,000. CrossGen Wealth LLC bought a new stake in Novartis during the fourth quarter worth $28,000. Bank of Jackson Hole Trust lifted its stake in Novartis by 425.0% during the fourth quarter. Bank of Jackson Hole Trust now owns 231 shares of the company’s stock worth $32,000 after purchasing an additional 187 shares during the last quarter. Finally, Valley Wealth Managers Inc. acquired a new stake in shares of Novartis in the 3rd quarter valued at $31,000. 13.12% of the stock is owned by institutional investors.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.